Video Experimental Relacionado
Updated: Jul 13, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Concentrados de factor de coagulación: pasado, presente y futuro
1University of North Carolina School of Medicine and Harold R Roberts Comprehensive Hemophilia Diagnostic and Treatment Center, Chapel Hill, NC, USA. Nigel_Key@med.unc.edu
Lancet (London, England)
|August 7, 2007
Resumen
Los concentrados de factor de coagulación han mejorado significativamente, reduciendo los riesgos de transmisión de patógenos para los pacientes con hemofilia. Los tratamientos futuros se centran en las proteínas de bioingeniería para mejorar la eficacia y reducir la inmunogenicidad.
Área de la Ciencia:
- Biotecnología La biotecnología es la biotecnología.
- Hematología Hematología.
- Prevención de las enfermedades infecciosas Prevención de las enfermedades infecciosas
Sus antecedentes:
- Las transfusiones con plasma agrupado en las décadas de 1970 y 1980 llevaron a una amplia propagación de infecciones por VIH y hepatitis C.
- Esta crisis estimuló el desarrollo de concentrados de factores de coagulación más seguros.
- Los concentrados actuales tienen un excelente historial de seguridad con respecto a la transmisión de patógenos.
Objetivo del estudio:
- Para revisar la evolución de los concentrados de factor de coagulación.
- Para resaltar los avances en seguridad y los desafíos terapéuticos restantes.
- Para discutir las direcciones futuras en las terapias de proteínas recombinantes.
Principales métodos:
- Revisión de los datos históricos sobre infecciones relacionadas con la transfusión.
- Análisis de los avances tecnológicos en la producción de concentrados de factores (cribado de donantes, tecnologías virucidas, tecnología de ADN recombinante).
- Discusión de los desafíos actuales y futuros en el tratamiento de la hemofilia.
Principales resultados:
- Los concentrados de factor recombinante han reducido drásticamente el riesgo de transmisión de patógenos transmitidos por la sangre.
- Los desafíos clave persisten, incluido el riesgo de transmisión de priones, la formación de alloanticuerpos y las disparidades de acceso global.
- Las proteínas de bioingeniería ofrecen potencial para mejorar las propiedades farmacocinéticas y reducir la inmunogenicidad.
Conclusiones:
- Se han logrado avances significativos en la seguridad de los concentrados de factor de coagulación.
- Abordar los desafíos restantes es crucial para la atención integral de la hemofilia.
- Es probable que las terapias futuras involucren proteínas recombinantes de bioingeniería avanzada.
Videos de Conceptos Relacionados
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:06Coagulation
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
01:09EDTA: Conditional Formation Constant
Each EDTA molecule has six binding sites: four carboxyl groups and two amino groups. The fully protonated form of EDTA is represented as H6Y2+. However, it can exist in different forms, H5Y+, H4Y, H3Y−, H2Y2−, and HY3−, depending on the pH of the solution. In very basic solutions with pH > 10.17, the fully deprotonated form, Y4−, is the predominant species that readily complexes with metal ions in a 1:1 ratio.
For the equilibrium reaction of the metal with the Y4− form of EDTA, the formation...
For the equilibrium reaction of the metal with the Y4− form of EDTA, the formation...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:26EDTA: Auxiliary Complexing Reagents
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...